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Abstract Previous studies suggest that localization of tumor
necrosis factor receptor (TNFR)-associated factor (TRAF) fam-
ily members is important for regulating their signal transduc-
tion. During a screen for TRAF3-associated proteins that po-
tentially alter TRAF3 subcellular localization and enable signal
transduction, we identi¢ed a novel protein, T3JAM (TRAF3-
interacting Jun N-terminal kinase (JNK)-activating modulator).
This protein associates speci¢cally with TRAF3 but not other
TRAF family members. Coexpression of T3JAM with TRAF3
recruits TRAF3 to the detergent-insoluble fraction. More im-
portantly, T3JAM and TRAF3 synergistically activate JNK but
not nuclear factor (NF)-UB. Our studies indicate that T3JAM
may function as an adapter molecule that speci¢cally regulates
TRAF3-mediated JNK activation.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Tumor necrosis factor receptor-associated factors (TRAFs),
are a family of adapters that mediate the activation of signal-
ing pathways downstream of tumor necrosis factor receptors
(TNFRs) [1]. Among six known TRAF family members,
TRAF3 has been shown to interact with many TNFR super-
family members including CD40, LT-LR and BR3 [2^5]. Stud-
ies have shown that TRAF3 may negatively regulate Jun
N-terminal kinase (JNK) and nuclear factor (NF)-UB signal-
ing [5^7]. However, TRAF3 also promotes NF-UB activation
in airway epithelial cells and may be able to activate p38 and
promote LT-LR-mediated death signaling [6,8,9]. These ¢nd-
ings suggest the presence of an intricate regulatory mechanism
that modulates the functional role of TRAF3.
When overexpressed, TRAF2, 5 and 6 activate the JNK
and NF-UB signaling pathways, possibly in membrane-local-
ized complexes [10,11]. TRAF3, on the other hand, is cyto-
solic and is unable to activate JNK or NF-UB when overex-
pressed, suggesting that recruitment to membrane-bound
complexes may be important for the activation of these path-
ways. We have shown that arti¢cial localization of TRAF3 to
the membrane enables TRAF3 to activate JNK but not NF-
UB [10]. In the cell, this may be mediated through interactions
between TRAF3 and other proteins.
Although multiple TRAF3-interacting proteins, including
p62 nucleoporin, the microtubule network-associated mole-
cule MIP-T3 and Act1, have been identi¢ed [12^14], the func-
tional relevance of these interactions in TRAF3-mediated sig-
naling is unclear. Here we report discovery of a novel protein,
T3JAM (TRAF3-interacting JNK-activating modulator).
T3JAM speci¢cally interacts with TRAF3 and alters the sub-
cellular localization of TRAF3 while promoting the speci¢c
activation of JNK signaling. To our knowledge this is the ¢rst
report describing a TRAF3-interacting protein that regulates
the speci¢c activation of the JNK pathway.
2. Materials and methods
2.1. Yeast two-hybrid screening
Yeast two-hybrid screening was performed as previously described
[15]. Full-length coding sequence for TRAF3 was used as bait to
screen a lambda phage mouse T cell library, kindly provided by Dr.
S. Elledge [16]. DNA was prepared from 40 positive clones and trans-
formed into Escherichia coli strain Topp10 and examined by restric-
tion analysis and sequencing.
2.2. Antibody production
A clone coding for amino acids 300^513 of T3JAM was subcloned
into the BamHI/XhoI sites of pGEX1VT and transformed into the
Topp10 strain of E. coli. Recombinant glutathione S-transferase
(GST)-T3JAM 300^513 was puri¢ed using standard GST puri¢cation
methods and the puri¢ed protein was sent to ProSci Incorporated for
antibody production in rabbits.
2.3. Plasmid construction
To obtain a full-length clone of T3JAM, we used the fragment from
the yeast two-hybrid screen (coding for amino acids 300^513) to probe
a murine T cell library using standard methods. Both strands of the
full-length T3JAM clone were sequenced, and the sequence deposited
into GenBank under accession number AY383616. Full-length and
truncated forms of T3JAM were ampli¢ed by polymerase chain reac-
tion (PCR) and subcloned into the BamHI/XhoI sites of pCMVmyc.
To make an in-frame GST fusion protein, T3JAM 300^513 was sub-
cloned into the BamHI/SalI sites of pEBG. The TRAF3/TRAF5 do-
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main-swapping plasmids and pEBB-HA-TRAF2, 3, 5 and 6 plasmids
were constructed as previously described [10,11].
2.4. mRNA quanti¢cation
RNA was isolated by standard guanidium isothiocyanate methods.
The cDNA template for quantitative real-time PCR analysis was then
synthesized and PCR was performed using the iCycler thermocycler
(Bio-Rad) as previously described [17,18]. Levels of the ribosomal
protein L32 were used to normalize expression levels of T3JAM in
di¡erent tissues. The primers used to amplify T3JAM are as follows:
T3JAM forward, ggagacatttcagctccaagtca; T3JAM reverse, tgtagcaat-
caccaccatcagc.
2.5. Fractionation, immunoprecipitation and Western blotting
For fractionation studies, cell transfection, lysis and fractionation
were performed as described previously [10]. Equivalent amounts of
cytoplasmic and pellet samples were prepared for Western blot anal-
ysis of TRAF distribution. For immunoprecipitation experiments,
cells were harvested and lysed in a Triton lysis bu¡er consisting of
20 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM ethylenediamine
tetraacetic acid (EDTA), 1% Triton X-100 and 10% glycerol plus a
protease inhibitor cocktail. An equal proportion of each sample was
removed prior to immunoprecipitation to analyze expression levels of
transfected constructs. Immunoprecipitation was performed using
rabbit anti-GST-T3JAM antibody (ProSci Incorporated), and samples
were analyzed by Western blot.
For analysis of endogenous murine T3JAM expression levels, bone
marrow, heart, kidney, liver, spleen and thymus were solubilized in
radioimmunoprecipitation assay (RIPA) bu¡er by sonication, and 30
Wg of protein from each organ was analyzed by Western blot using
rabbit anti-GST-T3JAM 300^513 antibodies.
Antibodies used in this manuscript include rabbit anti-GST-T3JAM
300^513 antibodies (ProSci Incorporated), the 12CA5 mouse anti-HA
antibody, the 9E10 mouse anti-myc antibody and mouse anti-GST
antibodies (Santa Cruz Biotechnologies).
2.6. In vitro kinase assay and gel shift analysis
JNK activity was measured as previously described [10]. Nuclear
extract isolation and electrophoretic mobility shift assays were per-
formed as described previously for NF-UB [19].
3. Results
3.1. Identi¢cation of T3JAM, a novel TRAF3-interacting
protein
To search for proteins that can recruit TRAF3 to the mem-
brane fraction and facilitate TRAF3-mediated signaling, we
conducted a yeast two-hybrid screen using full-length murine
TRAF3 as bait. From this screen many known TRAF3-inter-
acting proteins were identi¢ed, including TANK and p62 nu-
cleoporin. We also obtained numerous overlapping clones
representing a novel gene that we called T3JAM. To isolate
the full-length T3JAM sequence, we screened a murine T cell
cDNA library with the longest fragment from the yeast two-
hybrid screen (encoding 214 amino acids, T3JAM 300^513)
and recovered an insert of 2094 bases containing a single open
reading frame coding for a protein of 513 amino acids (Fig.
1A).
The University of California, Santa Cruz Genome Bioinfor-
matics Database (http://genome.ucsc.edu/) localized the
T3JAM sequence to chromosome 1 in the mouse and its ge-
nomic structure is predicted to contain 14 exons. T3JAM was
Fig. 1. T3JAM protein structural features. An alignment of the human and murine amino acid sequences of T3JAP are shown in A. Residues
identical to murine sequence are highlighted in black, missing residues are indicated by dashes and stop codons by periods. B: Graphical repre-
sentation of murine T3JAM protein structural features. Gray represents sequence with no signi¢cant homology to known conserved protein
motifs and the putative coiled-coil domain is indicated by diagonal lines.
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found to have a single human homolog (represented by DNA
sequence from PAC 434O14; GenBank accession numbers
AL049667, AK022798) on chromosome 1q32.3.341. The hu-
man gene codes for a product of 531 amino acids in length.
Murine and human T3JAM are 82% identical at the nucleo-
tide level, and have 66% amino acid identity and 73% amino
acid similarity (Fig. 1A). While the N-terminal half of T3JAM
contains no known conserved protein motifs, the C-terminal
half of T3JAM was found to contain a putative coiled-coil
domain homologous to the myosin tail heptad repeat and the
ezrin/radixin/moesin (ERM) family domain (Fig. 1B). Both of
these domains mediate protein^protein interactions, suggest-
ing a possible mechanism for T3JAM interaction with TRAF3
[20,21].
3.2. T3JAM is expressed in a tissue-speci¢c manner
To determine the tissue expression pattern of T3JAM in the
mouse we used quantitative real-time PCR and Western blot-
ting techniques. We found that T3JAM was preferentially ex-
pressed in the bone marrow, spleen and thymus and not
present in the heart, kidney or liver (Fig. 2A and B). Interest-
ingly, in addition to the band representing full-length T3JAM
protein (62 kDa), we observed bands of other sizes indicating
that T3JAM may be modi¢ed posttranslationally or its tran-
script may be alternatively spliced.
3.3. T3JAM interacts speci¢cally with TRAF3
To determine if T3JAM speci¢cally interacts with TRAF3
we coexpressed GST-tagged T3JAM with various HA-tagged
TRAF molecules and performed coimmunoprecipitation ex-
periments. In fractionation experiments, we found that
T3JAM is relatively detergent-insoluble and truncation mu-
tants showed that the N-terminal 300 amino acids of
T3JAM are responsible for localizing of T3JAM to the deter-
gent-insoluble fraction (data not shown). Because of this, it
was necessary to use a soluble truncation mutant of T3JAM
coding for amino acids 300^513 (T3JAM 300^513) for all
immunoprecipitation studies. As a positive control, TRAF3
was cotransfected with a construct coding for a GST-tagged
version of the CD40 cytoplasmic tail (pEBG-CD40ct). Fig. 3
demonstrates that TRAF3 strongly interacts with both the
CD40 cytoplasmic tail and with T3JAM. In contrast, neither
TRAF2 nor TRAF5 were able to associate with T3JAM. In
Fig. 2. Tissue-speci¢c expression of T3JAM. A: Total RNA was ex-
tracted from the indicated organs of C57B/6 mice and used to make
cDNA template. T3JAM expression was then assayed by quantita-
tive real-time PCR. Samples were run in triplicate and data are rep-
resented as relative expression units. B: RIPA extracts (30 Wg) from
indicated organs were analyzed by Western blot using anti-GST/
T3JAM 300^513.
Fig. 3. T3JAM speci¢cally associates with TRAF3. Indicated con-
structs were transfected into 293T cells using the calcium phosphate
method. GST-tagged T3JAM 300^513 was immunoprecipitated us-
ing rabbit polyclonal anti-GST antibodies and interaction with HA-
tagged TRAF2, 3, or 5 was assayed via Western blotting techniques
using the 12CA5 antibody. The data shown are representative of
four independent experiments.
Fig. 4. Mapping of TRAF3 and T3JAM interaction domains. Coim-
munoprecipitation experiments were carried out using HA-tagged
TRAF3/TRAF5 domain-swapping constructs depicted in A. Indi-
cated constructs were coexpressed with GST-tagged T3JAM 300^
513 in 293T cells and immune complexes were precipitated (IP) us-
ing rabbit anti-GST-T3JAM antibodies, separated by sodium dodec-
yl sulfate-polyacrylamide gel electrophoresis (SDS^PAGE) and im-
munoblotted (IB) with either 12CA5 mouse anti-HA or mouse anti-
GST antibodies (B). The data shown are representative of two inde-
pendent experiments.
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addition, we found that T3JAM was unable to interact with
TRAF6 (data not shown).
3.4. The coiled-coil domain of T3JAM mediates interaction
with the isoleucine zipper domain of TRAF3
Our yeast two-hybrid results showed that the C-terminal
coiled-coil-containing region of T3JAM (amino acids 300^
513) is su⁄cient to mediate interaction with TRAF3. We per-
formed coimmunoprecipitation experiments with T3JAM
300^513 and various mutants of TRAF3 to determine which
region of TRAF3 mediated interaction with T3JAM. Since
truncation mutants may adversely a¡ect the structural integ-
rity or solubility of TRAF3, we used domain-swapping con-
structs in which various regions of TRAF3 were replaced with
the homologous regions of TRAF5 [11]. As described above,
TRAF5 is unable to interact with T3JAM and thus any in-
teraction between T3JAM and one of these chimeric mole-
cules would presumably involve the portion of the mutant
contributed by TRAF3.
Constructs encoding either HA-tagged full-length TRAF3
or domain-swapping mutants in which various domains of
TRAF3 were replaced with those of TRAF5 (Fig. 4A) were
cotransfected with GST-tagged T3JAM 300^513. As seen in
Fig. 4B, full-length TRAF3 robustly interacts with T3JAM.
However, the construct that contains only the N-terminal
zinc-binding domain of TRAF3 (TRAF 35/250) is unable to
interact with T3JAM. Addition of the TRAF3 sequence cod-
ing for the isoleucine zipper (TRAF 35/329) allows for strong
association with T3JAM. Moreover, the protein containing all
TRAF3 sequences except the TRAF-C domain (TRAF 35/
403) also interacts with T3JAM. These results indicate that
the isoleucine zipper domain of TRAF3 mediates interaction
with the coiled-coil domain of T3JAM.
3.5. T3JAM recruits TRAF3 to the detergent-insoluble fraction
We had previously found that TRAF3 was the most soluble
member of the TRAF family, and its low presence in the
insoluble fraction correlated with a poor ability to activate
the JNK [10]. As T3JAM is an insoluble, TRAF3-interacting
protein, we hypothesized that it may be able to recruit
TRAF3 to the insoluble fraction. In Fig. 5 we examined the
solubility pro¢les of T3JAM and TRAF3 either alone or in
combination and found that T3JAM did indeed recruit a sig-
ni¢cant amount of TRAF3 protein to the pellet fraction.
While T3JAM consistently recruited TRAF3 to the insoluble
fraction in numerous experiments, we found that the degree of
recruitment was dependent upon the ratio of expression levels
of TRAF3 and T3JAM (data not shown). Thus, the stoichi-
ometry of TRAF3 and T3JAM may be an important factor in
the regulation of TRAF3.
3.6. Coexpression of T3JAM and TRAF3 causes the activation
of JNK but not NF-UB
We had previously observed a link between TRAF insolu-
bility and JNK activation [10]. In addition, preliminary func-
tional studies indicated that overexpressed T3JAM on its own
led to weak JNK activation and not of the type 1 NF-UB
pathway (data not shown). These observations led us to ex-
amine the e¡ect of combined TRAF3 and T3JAM expression
on JNK activation. As shown in Fig. 6, overexpression of
either TRAF3 or T3JAM alone in 293T cells does not lead
to signi¢cant JNK activation. However, coexpression of
T3JAM and TRAF3 strongly activates JNK, suggesting that
these two molecules have a synergistic e¡ect.
In the same cellular extracts, we simultaneously examined
the activation of the type 1 NF-UB pathway through a lucif-
erase reporter assay as well as through electrophoretic mobil-
ity shift assays using an NF-UB-speci¢c oligonucleotide probe
(Fig. 6). In both cases, T3JAM/TRAF3 coexpression appears
to have no e¡ect on the type 1 NF-UB pathway. These studies
demonstrate that the synergistic e¡ect between T3JAM and
TRAF3 is speci¢c for the activation of JNK and not NF-UB.
Thus, T3JAM may be a speci¢c regulator for TRAF3-medi-
ated JNK activation.
Fig. 5. T3JAM alters TRAF3 localization to the insoluble fraction
of cell lysates. 293T cells were transfected with the indicated plas-
mids. Cells were harvested as indicated in Section 2 and an equal
volume of each fraction was analyzed using Western blotting tech-
niques. Blots were probed with either the 12CA5 anti-HA antibody
or the 9E10 anti-myc antibody. The data shown are representative
of three independent experiments.
Fig. 6. T3JAM and TRAF3 cooperate to activate JNK signaling.
Indicated constructs were transfected into 293T cells using the calci-
um phosphate technique. Nuclear and cytoplasmic fractions were
isolated and used to test for NF-UB or JNK activation. NF-UB ac-
tivity was tested by luciferase reporter assay (top panel) and electro-
phoretic mobility shift assay (EMSA) (top middle panel). JNK ac-
tivity was examined by in vitro kinase assay from the same cell
extracts (bottom middle panel). Equivalent expression levels of HA-
JNK were determined by Western blotting using the 12CA5 anti-
body (bottom panel). The data shown are representative of three in-
dependent experiments.
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4. Discussion
While TRAF2, 5 and 6 all potently activate signal trans-
duction downstream of TNFRs, the role of TRAF3 in pro-
moting signaling events has been enigmatic. In this study, we
have identi¢ed a novel TRAF3-interacting protein that specif-
ically interacts with the isoleucine zipper of TRAF3 via its
coiled-coil domain. This interaction appears to recruit
TRAF3 to an as yet uncharacterized detergent-insoluble com-
plex where T3JAM cooperates with TRAF3 to speci¢cally
activate the JNK pathway. This scenario is consistent with
our previous results which showed that forced localization
of TRAF3 to the cell membrane allowed for activation of
the JNK pathway but not the NF-UB pathway [10]. In addi-
tion, TRAF3 has recently been shown to associate with a
number of detergent-insoluble subcellular microdomains in-
cluding the cytoskeleton and lipid rafts [13,22,23]. Thus, local-
ization of TRAF3 may be an important determinant in its
ability to activate speci¢c signaling pathways. Because
T3JAM is able to modulate the localization of TRAF3, it
may be one of the critical factors that determine which signal
transduction pathway is activated by TRAF3. Future studies
on the nature of the insoluble complex to which T3JAM re-
cruits TRAF3 and its role as a JNK-speci¢c signaling complex
should provide further insight into the mechanisms that reg-
ulate TRAF3-mediated signal transduction.
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